TORONTO, ON--(Marketwired - July 19, 2016) - Launching today, a groundbreaking precision diagnostic tool will help classify the aggressiveness of non-muscle invasive bladder tumours, announced Mount Sinai Services of Toronto, a global provider of customized clinical laboratory and research services. The new technology is marketed by iTP Biomedica as BladderPredictT, and is the first of a series of proprietary next generation sequencing diagnostic tests resulting from collaborative work at the Lunenfeld-Tanenbaum Research Institute and Mount Sinai Services.
